As mentioned above, we found strong correlations between FDG-PET and CSF tau biomarkers, but no significant association between FDG uptake and tau PET as observed correlations may reflect group-level differences across diagnostic categories, rather than within-group relationships limited by the low number of AD patients that underwent 18F-Flortaucipir-PET in our cohort restricting the range of tau pathology. Here, MAPT is linked to Alzheimer disease.